European Union International Standa... NGOs United Nations
Algeria Angola Benin Botswana Burkina Faso Burundi Cameroon Cape Verde Islands Central African Republic Chad Comoros Congo (Brazzaville) Congo, Democratic Re... Cote d'Ivoire Djibouti Equatorial Guinea Eritrea Ethiopia Gabon Gambia Ghana Guinea Guinea-Bissau Kenya Lesotho Liberia Libya Madagascar Malawi Mali Mauritania Mauritius Mayotte Morocco Mozambique Namibia Niger Nigeria Reunion Rwanda Sao Tome & Principe Senegal Seychelles Sierra Leone Somalia South Africa St. Helena Sudan Swaziland Tanzania Togo Tunisia Uganda Western Sahara Zambia Zimbabwe
|
Medicines and Healthcare products Regulatory Agency (MHRA)
| Report Title: |
How We Regulate Nanotechnology |
| Report ID: |
183 |
| Date: |
2/7/2008 |
| Author: |
Medicines and Healthcare Products Regulatory Agency |
| Report Type: |
Webpage |
| URL: |
[index.htm] |
| Country: |
United Kingdom |
| Organization: |
Medicines and Healthcare products Regulatory Agency (MHRA) |
| Summary: |
This brief webpage summarizes the UK governments efforts to regulate nanotechnology in the medical sector and provides links to relevant reports, papers, and efforts. The Nanoscience and nanotechnologies: opportunities and uncertainties report called for the Department of Health to review its regulations to ensure that particle size is used as a factor in determining medicine safety. While at present there are no regulations specifically targeting nanotechnology in medical devices or medicines, existing regulations are being examined. The European Medicines Agency (EMEA) examined this issue in a paper, and a European Medical Devices Expert Working Group is currently assessing the existing regulatory framework. Currently the MHRA believes that existing regulations for medical devices and medicines are sufficient for adequately regulating the use of nanotechnology in those products. |
| Archived Copy: |
Michael Vincent MHRA (2008), How we regulate nanotechnology_183_4942.pdf |
 |
|
|